A team of US researchers, including a scientist of Indian-origin, has shown for the first time that Covid-19 vaccines and prior Covid infections can provide broad immunity against other similar coronaviruses.
The findings build a rationale for universal coronavirus vaccines that could prove useful in the face of future epidemics.
"Until our study, what hasn't been clear is if you get exposed to one coronavirus, could you have cross-protection across other coronaviruses? And we showed that is the case," said lead author Pablo Penaloza-MacMaster, Assistant Professor of Microbiology-Immunology at North-western University's Feinberg School of Medicine.
Penaloza-MacMaster collaborated with North-western Medicine physician, Igor Koralnik and Lavanya Visvabharathy, a post-doctoral research associate at Feinberg, to evaluate immune responses in humans who received Covid vaccines as well as in Covid patients.
"We found that these individuals developed antibody responses that neutralised a common cold coronavirus, HCoV-OC43," Penaloza-MacMaster said.
"We are now measuring how long this cross-protection lasts."
The three main families of coronaviruses that cause human disease are Sarbecovirus, which includes the SARS-CoV-1 strain that was responsible for the 2003 outbreak of Severe Acute Respiratory Syndrome (SARS).
Other coronaviruses are SARS-CoV-2, which is responsible for Covid-19 pandemic; Embecovirus (that includes OC43) which is often responsible for the common cold; and Merbecovirus, which is the virus responsible for Middle East Respiratory Syndrome (MERS), first reported in 2012.
During the study published in the Journal of Clinical Investigation, plasma from humans who had been vaccinated against SARS-CoV-2 produced antibodies that were cross-reactive (provided protection) against SARS-CoV-1 and the common cold coronavirus (OC43).
The study found mice immunised with a SARS-CoV-1 vaccine developed in 2004 generated immune responses that protected them from intranasal exposure by SARS-CoV-2.
The team found prior coronavirus infections can protect against subsequent infections with other coronaviruses.
Mice that had been immunised with Covid-19 vaccines and later were exposed to the common cold coronavirus were partially protected against the common cold but the protection was much less robust, the study found.
The reason, the scientists explained, is because both SARS-CoV-1 and SARS-CoV-2 are genetically similar while the common cold coronavirus is more divergent from SARS-CoV-2.
"As long as the coronavirus is greater than 70 per cent related, the mice were protected," Penaloza-MacMaster said.
"If they were exposed to a very different family of coronaviruses, the vaccines might confer less protection."
Given how different each coronavirus family is, that answer is "likely no", said the study authors.
However, there may be a path forward for developing a vaccine for each coronavirus family (Sarbecovirus, Embecovirus and Merbecovirus), they said.
--IANS
na/khz/ksk/
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)